Article info

Download PDFPDF

A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)

Authors

  1. Correspondence to Professor Peter Pickkers; peter.pickkers{at}radboudumc.nl
View Full Text

Citation

Geven C, Blet A, Kox M, et al
A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)

Publication history

  • Received May 29, 2018
  • Revised September 14, 2018
  • Accepted December 31, 2018
  • First published February 6, 2019.
Online issue publication 
February 06, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.